Tim Anderson
Stock Analyst at B of A Securities
(4.57)
# 233
Out of 5,049 analysts
47
Total ratings
76.92%
Success rate
15.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $646.87 | -3.07% | 3 | Oct 29, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $198 → $204 | $186.97 | +9.11% | 8 | Oct 15, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $24.85 | +20.72% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $315.59 | -13.81% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $55.00 | +58.20% | 1 | Aug 28, 2025 | |
| MTSR Metsera | Maintains: Buy | $45 → $50 | $81.55 | -38.69% | 2 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $9.87 | +153.29% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $219.04 | -6.87% | 7 | Apr 28, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $123.40 | +2.11% | 3 | Mar 5, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $24.33 | +39.75% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $112 | $85.78 | +30.57% | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $46.63 | +35.11% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $156.74 | +13.56% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $937.44 | +6.35% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $126.57 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $83.77 | - | 1 | Sep 22, 2017 |
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $646.87
Upside: -3.07%
Johnson & Johnson
Oct 15, 2025
Maintains: Neutral
Price Target: $198 → $204
Current: $186.97
Upside: +9.11%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $24.85
Upside: +20.72%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $315.59
Upside: -13.81%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $55.00
Upside: +58.20%
Metsera
Aug 28, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $81.55
Upside: -38.69%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $9.87
Upside: +153.29%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $219.04
Upside: -6.87%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $123.40
Upside: +2.11%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $24.33
Upside: +39.75%
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $85.78
Upside: +30.57%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $46.63
Upside: +35.11%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $156.74
Upside: +13.56%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $937.44
Upside: +6.35%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $126.57
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $83.77
Upside: -